Heart Attack

Cardio Diagnostics Holdings, Inc. Expands HeartRisk™ Platform Offering to Diverse Markets in Conjunction with Nationwide Rollout

Transformative Cardiovascular Risk Management Solutions Extend Beyond Traditional Sectors to Include Federal and State Correctional Facilities, Broker and Benefits Organizations,…

1 month ago

Meridian Analytics Rebrands to Discern Health, Focused on Human-Centric Predictive Care

Discern Health’s predictive models allow for life-changing health events to be anticipated so preventative measures can be applied to reduce…

1 month ago

Veradigm and American College of Cardiology Launch Influenza Vaccination Education Initiative to Improve Cardiovascular Health

CHICAGO--(BUSINESS WIRE)--#healthIT--Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions announced today the launch of TRANSFORM…

1 month ago

Veradigm and American College of Cardiology Launch Influenza Vaccination Education Initiative to Improve Cardiovascular Health

CHICAGO--(BUSINESS WIRE)--#healthIT--Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions announced today the launch of TRANSFORM…

1 month ago

Cardio Diagnostics Holdings, Inc. Expands Partnership with Family Medicine Specialists to Bring Its Specialty Cardiology Tests to Select Walmart Supercenters

Agreement is the first introduction of AI-driven epigenetic heart attack risk assessment and coronary heart disease detection tests in a…

2 months ago

Cardio Diagnostics Holdings, Inc. Expands Partnership with Family Medicine Specialists to Bring Its Specialty Cardiology Tests to Select Walmart Supercenters

Agreement is the first introduction of AI-driven epigenetic heart attack risk assessment and coronary heart disease detection tests in a…

2 months ago

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize…

2 months ago

Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Toronto, Ontario--(Newsfile Corp. - January 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a…

2 months ago